No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard Medical Research Council induction chemotherapy - Reply [Letter]

Burnett, Alan Kenneth and Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 2013. No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard Medical Research Council induction chemotherapy - Reply [Letter]. Journal of Clinical Oncology 31 (13) , pp. 1700-1701. 10.1200/JCO.2013.48.6571

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	American Society of Clinical Oncology
ISSN:	0732-183X
Last Modified:	24 Oct 2022 11:56
URI:	https://orca.cardiff.ac.uk/id/eprint/49810

Actions (repository staff only)

Edit Item